News
PSNL
16.46
-0.66%
-0.11
Top Personalis Executive Makes Notable Insider Move With Recent Stock Sale
TipRanks · 3d ago
Weekly Report: what happened at PSNL last week (0914-0918)?
Weekly Report · 5d ago
Noteworthy ETF Outflows: ARKG, TXG, PSNL, GH
NASDAQ · 09/16 15:03
Weekly Report: what happened at PSNL last week (0907-0911)?
Weekly Report · 09/14 10:15
Cathie Wood's weekly recap: loads Rocket Lab, Block; cuts Palantir, Tempus AI
Seeking Alpha · 09/07 11:10
Weekly Report: what happened at PSNL last week (0831-0904)?
Weekly Report · 09/07 10:09
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels - Heard on the Street
The Wall Street Journal · 09/04 09:30
Tempus AI upgraded at Piper Sandler on growth drivers
Seeking Alpha · 09/01 15:49
Tempus AI upgraded to Overweight from Neutral at Piper Sandler
TipRanks · 09/01 09:20
Weekly Report: what happened at PSNL last week (0824-0828)?
Weekly Report · 08/31 10:15
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.
Barchart · 08/26 10:50
What’s Going On With Tempus AI Stock on Monday?
Benzinga · 08/24 18:02
Personalis falls amid a downgrade as a competitive bid appears unlikely
Seeking Alpha · 08/24 17:14
Weekly Report: what happened at PSNL last week (0817-0821)?
Weekly Report · 08/24 10:16
Personalis (PSNL) Gets a Hold from Lake Street
TipRanks · 08/21 13:25
Personalis secures new Million Veteran Program task order
TipRanks · 08/20 21:31
On Aug 20, Personalis Received A New Task Order Under Its Contract With U.S. Department Of Veterans Affairs For VA MVP; New Task Order Effective Sept 30, 2026, Valued Up To $18.30M
Benzinga · 08/20 20:54
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Seeking Alpha · 08/20 12:00
Moderna Doubles, Gold Rallies To $4,500 As Dollar Sinks: Stock Market Today
Benzinga · 08/19 17:10
Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why
TipRanks · 08/19 17:04
More
Webull provides a variety of real-time PSNL stock news. You can receive the latest news about Personalis through multiple platforms. This information may help you make smarter investment decisions.
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.